Startup Licenses “Vaginal Seeding” Approach

Boston-based Commense plans to develop microbial and nonmicrobial interventions aimed at improving child health.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY, PEDROSERAPIOMaria Dominguez-Bello of the New York University (NYU) School of Medicine and colleagues in February published the results of a small study showing that swabbing babies born by Cesarean section (C-section) with microbes from their mothers’ birth canals could partially restore the microbial diversity that is lacking when compared with vaginally delivered infants. Now, the startup Commense—of which Dominguez-Bello is a cofounder—has obtained an exclusive license from NYU to extend “this approach by developing microbial and non-microbial interventions that could benefit millions of children each year worldwide,” the company said in a statement released today (March 31).

The approach, called “vaginal seeding,” is not without its critics. In a February editorial published in The BMJ, researchers at Imperial College London and their colleagues urged clinicians against the “increasingly popular but unproved practice.” The authors cited the risk of transferring pathogenic microbes from mother to child, among other things.

“To be clear, if a mother tests positive for any pathogens that could harm her child, we agree that clinicians should not perform vaginal seeding,” Rob Knight of the University of California, San Diego, and Jack Gilbert of the University of Chicago wrote in a March opinion piece for The Scientist. “But based on the evidence to date that your child’s microbiome at birth is important and modifiable, we think that parents should make ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies